DrugPatentWatch Database Preview
Details for New Drug Application (NDA): 205525
» See Plans and Pricing
NDA 205525 describes SYNDROS, which is a drug marketed by Benuvia and is included in one NDA. There are three patents protecting this drug and two Paragraph IV challenges. Additional details are available on the SYNDROS profile page.
The generic ingredient in SYNDROS is dronabinol. There are eleven drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the dronabinol profile page.
The generic ingredient in SYNDROS is dronabinol. There are eleven drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the dronabinol profile page.
Summary for 205525
| Tradename: | SYNDROS |
| Applicant: | Benuvia |
| Ingredient: | dronabinol |
| Patents: | 3 |
| Formulation / Manufacturing: | see details |
Medical Subject Heading (MeSH) Categories for 205525
Paragraph IV (Patent) Challenges for 205525
| Tradename | Dosage | Ingredient | NDA | Submissiondate |
|---|---|---|---|---|
| SYNDROS | SOLUTION;ORAL | dronabinol | 205525 | 2017-04-17 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;ORAL | Strength | 5MG/ML | ||||
| Approval Date: | Mar 23, 2017 | TE: | RLD: | Yes | |||||
| Patent: | Start Trial | Patent Expiration: | Aug 6, 2028 | Product Flag? | Y | Substance Flag? | Y | Delist Request? | |
| Patent: | Start Trial | Patent Expiration: | Aug 6, 2028 | Product Flag? | Y | Substance Flag? | Y | Delist Request? | |
| Patent: | Start Trial | Patent Expiration: | Aug 6, 2028 | Product Flag? | Y | Substance Flag? | Y | Delist Request? | |
Complete Access Available with Subscription
